MY142376A - Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them - Google Patents

Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them

Info

Publication number
MY142376A
MY142376A MYPI20033852A MYPI20033852A MY142376A MY 142376 A MY142376 A MY 142376A MY PI20033852 A MYPI20033852 A MY PI20033852A MY PI20033852 A MYPI20033852 A MY PI20033852A MY 142376 A MY142376 A MY 142376A
Authority
MY
Malaysia
Prior art keywords
heparin
mixtures
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
MYPI20033852A
Inventor
Biberovic Vesna
Grondard Luc
Mourier Pierre
Viskov Christian
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MY142376A publication Critical patent/MY142376A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

THE PRSENT INVENTION RELATES TO MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN HAVING A MEAN MOLECULAR WEIGHT OF 1500 TO 3000 DALTONS AND AN ANTI-XA/ANTI-IIA RATIOP GREATER THAN 30, THEIR METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MYPI20033852A 2002-10-10 2003-10-09 Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them MY142376A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212584A FR2845686B1 (en) 2002-10-10 2002-10-10 MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
MY142376A true MY142376A (en) 2010-11-30

Family

ID=32039597

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20033852A MY142376A (en) 2002-10-10 2003-10-09 Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them

Country Status (35)

Country Link
EP (1) EP1556414B1 (en)
JP (2) JP5021898B2 (en)
CN (6) CN101810637A (en)
AT (1) ATE548393T1 (en)
AU (1) AU2003300161B2 (en)
BR (1) BR0315149A (en)
CA (1) CA2501546C (en)
CY (1) CY1112808T1 (en)
DK (1) DK1556414T3 (en)
EC (1) ECSP055722A (en)
ES (1) ES2383597T3 (en)
FR (1) FR2845686B1 (en)
GT (1) GT200300181A (en)
HN (1) HN2003000312A (en)
IL (1) IL167868A (en)
MA (1) MA27398A1 (en)
MX (1) MXPA05003321A (en)
MY (1) MY142376A (en)
NI (1) NI200300087A (en)
NO (1) NO20052170L (en)
NZ (1) NZ539229A (en)
OA (1) OA12940A (en)
PA (1) PA8584201A1 (en)
PE (1) PE20040507A1 (en)
PT (1) PT1556414E (en)
RS (1) RS20050274A (en)
RU (1) RU2332424C2 (en)
SI (1) SI1556414T1 (en)
SV (1) SV2004001626A (en)
TN (1) TNSN05101A1 (en)
TW (1) TWI332010B (en)
UA (1) UA81925C2 (en)
UY (1) UY28016A1 (en)
WO (1) WO2004033503A1 (en)
ZA (1) ZA200502787B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845686B1 (en) * 2002-10-10 2013-08-30 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2857971B1 (en) * 2003-07-24 2005-08-26 Aventis Pharma Sa MIXTURES OF HEPARIN DERIVED OLIGOSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN101495517B (en) * 2006-05-25 2012-10-10 莫曼塔医药品有限公司 Low molecular weight heparin composition and uses thereof
CA2641571C (en) 2006-12-05 2010-01-19 Glycoscience Laboratories, Inc. Treatment of osteoarthritis
CA2750188C (en) * 2009-02-02 2016-11-29 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and compositions containing same
EP2233145A1 (en) 2009-03-19 2010-09-29 Sanofi-Aventis A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
EP2399591A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
EP2399592A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP2399590A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
EP2399593A1 (en) 2010-06-28 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in orthopaedic surgery with improved benefit-risk profile
JP2012046511A (en) * 2010-07-30 2012-03-08 Otsuka Chem Co Ltd Pharmaceutical agent containing low molecular weight polysulfated hyaluronic acid derivative
EP2617737B1 (en) * 2010-09-14 2017-03-01 University Of Miyazaki High purity heparin and production method therefor
WO2012055843A1 (en) 2010-10-28 2012-05-03 Aventis Pharma S.A. Semuloparin for the prevention of major venous thromboembolism in a patient undergoing major abdominal surgery
EP2446891A1 (en) 2010-10-28 2012-05-02 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in major abdominal surgery with improved safety in terms of clinically relevant bleedings and major bleedings
WO2012072799A1 (en) 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample
AR085961A1 (en) 2011-04-11 2013-11-06 Sanofi Sa POLISACARIDS THAT HAVE TWO SITES OF UNION TO ANTHROMBIN III, METHOD TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
EP2548561A1 (en) 2011-07-22 2013-01-23 Aventis Pharma S.A. Semuloparin for improving the survival of patients with locally advanced cancer
WO2013044793A1 (en) * 2011-09-26 2013-04-04 Xu Meiying High-purity heparin benzyl ester salt, preparation method therefor and application thereof
CN102633908A (en) * 2012-05-02 2012-08-15 雷晓刚 Method for preparing high-quality LMW (low molecular weight) heparins
ES2445494B1 (en) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedure for obtaining low and very low molecular weight heparins
US9873712B2 (en) * 2014-10-03 2018-01-23 Amphastar Pharmaceuticals, Inc. Method of purifying idraparinux sodium
JP6741277B2 (en) * 2015-12-30 2020-08-19 シェンツェン ヘパリンク ファーマスーティカル グループ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｈｅｐａｌｉｎｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． Sulfated heparin-derived oligosaccharide and its preparation method and application
CZ308106B6 (en) * 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, their preparation and their use
CN110917208B (en) * 2019-12-27 2021-02-12 浙江医院 Application of sulfated mannoglucuronhexaose in preventing and treating atherosclerosis
CN117534776B (en) * 2023-09-26 2026-03-03 南京健友生化制药股份有限公司 Impurity removal method for enox esterification reaction liquid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2482611B1 (en) 1980-05-14 1986-03-07 Pharmindustrie NOVEL SULFATED POLYSACCHARIDES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
FR2504928A1 (en) * 1981-04-29 1982-11-05 Choay Sa SHORT CHAIN OLIGOSACCHARIDES HAVING BIOLOGICAL PROPERTIES, PREPARATION THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
FR2584606A1 (en) * 1985-07-12 1987-01-16 Dropic USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE
FR2669932B1 (en) * 1990-12-03 1994-07-01 Sanofi Sa NOVEL HEPAROSANE-N, O-SULFATE, ITS PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
ES2161615B1 (en) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa COMPOSITIONS OF HEPARINS OF VERY LOW MOLECULAR WEIGHT.
JP4897991B2 (en) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ Ultra low molecular weight heparin composition
FR2807043B1 (en) * 2000-03-28 2002-11-22 Aventis Pharma Sa PHARMACEUTICAL COMPOSITION CONTAINING OLIGOSACCHARIDES, NEW OLIGOSACCHARIDES AND THEIR PREPARATION
FR2811992B1 (en) * 2000-07-21 2003-07-04 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2845686B1 (en) * 2002-10-10 2013-08-30 Aventis Pharma Sa MIXTURES OF HEPARIN-DERIVED POLYSACCHARIDES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
IL167868A (en) 2010-05-31
NI200300087A (en) 2012-02-02
PT1556414E (en) 2012-05-21
TWI332010B (en) 2010-10-21
EP1556414A1 (en) 2005-07-27
CY1112808T1 (en) 2016-02-10
JP2006517185A (en) 2006-07-20
JP2012051926A (en) 2012-03-15
MXPA05003321A (en) 2005-07-05
GT200300181A (en) 2004-03-24
SI1556414T1 (en) 2012-06-29
AU2003300161B2 (en) 2009-08-27
NO20052170D0 (en) 2005-05-03
FR2845686A1 (en) 2004-04-16
CN101812189A (en) 2010-08-25
CN1798771A (en) 2006-07-05
PE20040507A1 (en) 2004-10-13
ES2383597T3 (en) 2012-06-22
NO20052170L (en) 2005-07-07
RU2005113987A (en) 2006-01-27
AU2003300161A1 (en) 2004-05-04
HN2003000312A (en) 2005-10-20
EP1556414B1 (en) 2012-03-07
ECSP055722A (en) 2005-07-06
TNSN05101A1 (en) 2007-05-14
UY28016A1 (en) 2004-04-30
PA8584201A1 (en) 2004-08-31
ZA200502787B (en) 2005-10-18
WO2004033503A1 (en) 2004-04-22
MA27398A1 (en) 2005-06-01
CA2501546C (en) 2012-04-03
DK1556414T3 (en) 2012-06-25
JP5021898B2 (en) 2012-09-12
OA12940A (en) 2006-10-13
SV2004001626A (en) 2004-03-08
FR2845686B1 (en) 2013-08-30
CN101817940A (en) 2010-09-01
CN101812190A (en) 2010-08-25
CN101810637A (en) 2010-08-25
TW200418882A (en) 2004-10-01
RU2332424C2 (en) 2008-08-27
JP5389140B2 (en) 2014-01-15
CN101812139A (en) 2010-08-25
NZ539229A (en) 2008-03-28
CA2501546A1 (en) 2004-04-22
UA81925C2 (en) 2008-02-25
ATE548393T1 (en) 2012-03-15
BR0315149A (en) 2005-08-16
RS20050274A (en) 2007-06-04

Similar Documents

Publication Publication Date Title
MY142376A (en) Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
MY148379A (en) Ultra high performance clarified gellan gums
ATE345361T1 (en) SILYL ESTER COPOLYMER COMPOSITIONS
WO2002023190A3 (en) Methods and products related to low molecular weight heparin
AU2003263753A1 (en) Molecular weight reduction of polysaccharides by electron beams
MX2022007082A (en) Oral composition with polymeric component.
ES2161615A1 (en) Compositions comprising low molecular weight Heparin
BR0316915A (en) Composition of manocomposite, method to prepare it and its use
NO20015224D0 (en) Soluble branched polymers of glucose and their preparation
AR029865A1 (en) MIXTURES OF SULFATED POLYSACARIDS DERIVED FROM HEPARINE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PT983304E (en) DERMATAN DISSULFATE, AN INHIBITOR OF TROMBIN PRODUCTION AND COMPLEMENT ACTIVATION
CY1111165T1 (en) MIXES OF OLIGOSACHARS COMING FROM USRIN, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOUNDS CONTAINING THEM
AU2002218748A1 (en) High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity
IS2783B (en) A pharmaceutical composition that covers chitosomes
TW200500452A (en) Process for preparing a flame retardant polyamide compound
WO2003032925A3 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2003225201A1 (en) Hydrolysis resistant polyester compositions and related articles and methods
MXPA04002585A (en) Modified shock-resistant polymer compositions.
DE69313826D1 (en) SULFATED POLYSACCHARIDES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND THEIR USE
WO2005002343A3 (en) Beta-glucan-containing products, methods of making same, and uses therefor
WO2002062868A1 (en) Polytrimethylene terephthalate and process for producing the same
TW200704403A (en) Dilution resistant viscoelastic compositions
CA2160440A1 (en) Method of Manufacturing Non-Absorbable Synthetic Sulfated Polysaccharides
AU4709997A (en) Preparation of chemically reactive polysaccharides
EP1306389A3 (en) Sulfated fucan oligosaccharide